ID   222
AC   CVCL_1T15
DR   BTO; BTO:0004035
DR   BioSample; SAMN03151885
DR   cancercelllines; CVCL_1T15
DR   IARC_TP53; 5549
DR   Wikidata; Q54583269
RX   PubMed=1918981;
RX   PubMed=2227544;
RX   PubMed=8557231;
RX   PubMed=9554442;
RX   PubMed=22710073;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a PA-1 derivative (PubMed=22710073). Originally thought to be an ovarian carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00454.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro316Pro (c.948C>T); ClinVar=VCV000750727; Zygosity=Heterozygous (PubMed=8557231).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C8114; Ovarian mixed germ cell tumor
DI   ORDO; Orphanet_180234; Mixed germ cell tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0479 ! PA-1
SX   Female
AG   12Y
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 05-10-23; Version: 18
//
RX   PubMed=1918981; DOI=10.4049/jimmunol.147.8.2609;
RA   Morimoto H., Safrit J.T., Bonavida B.;
RT   "Synergistic effect of tumor necrosis factor-alpha- and diphtheria
RT   toxin-mediated cytotoxicity in sensitive and resistant human ovarian
RT   tumor cell lines.";
RL   J. Immunol. 147:2609-2616(1991).
//
RX   PubMed=2227544; DOI=10.1016/0090-8258(90)90068-V;
RA   Bonavida B., Tsuchitani T., Zighelboim J., Berek J.S.;
RT   "Synergy is documented in vitro with low-dose recombinant tumor
RT   necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells.";
RL   Gynecol. Oncol. 38:333-339(1990).
//
RX   PubMed=8557231; DOI=10.1006/gyno.1996.0014;
RA   Skilling J.S., Squatrito R.C., Connor J.P., Niemann T., Buller R.E.;
RT   "p53 gene mutation analysis and antisense-mediated growth inhibition
RT   of human ovarian carcinoma cell lines.";
RL   Gynecol. Oncol. 60:72-80(1996).
//
RX   PubMed=9554442; DOI=10.1093/jnci/90.8.597;
RA   Sabichi A.L., Hendricks D.T., Bober M.A., Birrer M.J.;
RT   "Retinoic acid receptor beta expression and growth inhibition of
RT   gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl)
RT   retinamide.";
RL   J. Natl. Cancer Inst. 90:597-605(1998).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//